These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer. Todorova K; Metodiev MV; Metodieva G; Mincheff M; Fernández N; Hayrabedyan S Horm Cancer; 2017 Feb; 8(1):28-48. PubMed ID: 28050800 [TBL] [Abstract][Full Text] [Related]
3. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102 [TBL] [Abstract][Full Text] [Related]
4. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Hu Y; Dobi A; Sreenath T; Cook C; Tadase AY; Ravindranath L; Cullen J; Furusato B; Chen Y; Thangapazham RL; Mohamed A; Sun C; Sesterhenn IA; McLeod DG; Petrovics G; Srivastava S Clin Cancer Res; 2008 Aug; 14(15):4719-25. PubMed ID: 18676740 [TBL] [Abstract][Full Text] [Related]
5. Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer. Kolar Z; Burdova A; Jamaspishvili T; Bouchal J; Kucerova R; Bienova M; Kral M; Student V Neoplasma; 2014; 61(1):9-16. PubMed ID: 24195515 [TBL] [Abstract][Full Text] [Related]
6. Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer. Knuuttila M; Mehmood A; Mäki-Jouppila J; Ryberg H; Taimen P; Knaapila J; Ettala O; Boström PJ; Ohlsson C; Venäläinen MS; Laiho A; Elo LL; Sipilä P; Mäkelä SI; Poutanen M Endocr Relat Cancer; 2018 Sep; 25(9):807-819. PubMed ID: 29773553 [TBL] [Abstract][Full Text] [Related]
7. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cai C; Wang H; Xu Y; Chen S; Balk SP Cancer Res; 2009 Aug; 69(15):6027-32. PubMed ID: 19584279 [TBL] [Abstract][Full Text] [Related]
8. Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer. Thangapazham R; Saenz F; Katta S; Mohamed AA; Tan SH; Petrovics G; Srivastava S; Dobi A BMC Cancer; 2014 Jan; 14():16. PubMed ID: 24418414 [TBL] [Abstract][Full Text] [Related]
9. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models. Linn DE; Bronson RT; Li Z PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911 [TBL] [Abstract][Full Text] [Related]
10. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. Setlur SR; Mertz KD; Hoshida Y; Demichelis F; Lupien M; Perner S; Sboner A; Pawitan Y; Andrén O; Johnson LA; Tang J; Adami HO; Calza S; Chinnaiyan AM; Rhodes D; Tomlins S; Fall K; Mucci LA; Kantoff PW; Stampfer MJ; Andersson SO; Varenhorst E; Johansson JE; Brown M; Golub TR; Rubin MA J Natl Cancer Inst; 2008 Jun; 100(11):815-25. PubMed ID: 18505969 [TBL] [Abstract][Full Text] [Related]
11. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer. Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739 [TBL] [Abstract][Full Text] [Related]
12. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Furusato B; Gao CL; Ravindranath L; Chen Y; Cullen J; McLeod DG; Dobi A; Srivastava S; Petrovics G; Sesterhenn IA Mod Pathol; 2008 Feb; 21(2):67-75. PubMed ID: 18065961 [TBL] [Abstract][Full Text] [Related]
13. [The progress of TMPRSS2-ETS gene fusions and their mechanism in prostate cancer]. Guo XQ; Gui YT; Cai ZM Yi Chuan; 2011 Feb; 33(2):117-22. PubMed ID: 21377967 [TBL] [Abstract][Full Text] [Related]
14. Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma. Wang L; Williamson SR; Zhang S; Huang J; Montironi R; Davison DD; Wang M; Yao JL; Lopez-Beltran A; Osunkoya AO; MacLennan GT; Baldridge LA; Du X; Cheng L Mol Carcinog; 2015 Sep; 54(9):900-7. PubMed ID: 24777847 [TBL] [Abstract][Full Text] [Related]
15. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Rickman DS; Pflueger D; Moss B; VanDoren VE; Chen CX; de la Taille A; Kuefer R; Tewari AK; Setlur SR; Demichelis F; Rubin MA Cancer Res; 2009 Apr; 69(7):2734-8. PubMed ID: 19293179 [TBL] [Abstract][Full Text] [Related]
16. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163 [TBL] [Abstract][Full Text] [Related]
17. TMPRSS2-ERG Fusion Promotes Recruitment of Regulatory T cells and Tumor Growth in Prostate Cancer. Shan L; Ji T; Su X; Shao Q; Du T; Zhang S Am J Med Sci; 2018 Jul; 356(1):72-78. PubMed ID: 30049331 [TBL] [Abstract][Full Text] [Related]
18. Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene. Ribeiro FR; Paulo P; Costa VL; Barros-Silva JD; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR PLoS One; 2011; 6(7):e22317. PubMed ID: 21814574 [TBL] [Abstract][Full Text] [Related]
19. TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers. Hägglöf C; Hammarsten P; Strömvall K; Egevad L; Josefsson A; Stattin P; Granfors T; Bergh A PLoS One; 2014; 9(2):e86824. PubMed ID: 24505269 [TBL] [Abstract][Full Text] [Related]
20. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion. Gerashchenko GV; Mevs LV; Chashchina LI; Pikul MV; Gryzodub OP; Stakhovsky EO; Kashuba VI Exp Oncol; 2018 Jun; 40(2):101-108. PubMed ID: 29949537 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]